Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Nov;85(11):1722–1730. doi: 10.1054/bjoc.2001.2136

A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2

P Correale 1, L Micheli 2, M T Del Vecchio 3, M Sabatino 1, R Petrioli 1, D Pozzessere 1, S Marsili 1, G Giorgi 2, L Lozzi 4, P Neri 4, G Francini 1
PMCID: PMC2363980  PMID: 11742494

Abstract

Bone metastases are one of the most common events in patients with prostate carcinoma. PTH-rP, a protein produced by prostate carcinoma and other epithelial cancers, is a key agent for the development of bone metastases. A PTH-rP-derived peptide, designated PTR-4 was identified, which is capable to bind HLA-A2.1 molecules and to generate PTH-rP-specific cytotoxic T cell (CTL) lines from healthy HLA-A2.1+ individual peripheral-blood-mononuclear-cells (PBMC). In this model, we investigated the in vitro possibility of generating an efficient PTH-rP specific CTL response by cyclical stimulations with IL-2 and PTR-4 peptide-pulsed autologous dendritic cells (DC), of HLA-A2.1+ tumour infiltrating lymphocytes (TIL) derived from a patient with metastatic prostate carcinoma. A T cell line generated in this way (called TM-PTR-4) had a CD3+, CD5+, CD4−, CD8+, CD45Ro+, CD56− immunophenotype and a HLA-A2.1 restricted cytotoxic activity to PTR-4-peptide pulsed CIR-A2 (HLA-A2.1+) target cells, PTH-rP+/HLA-A2.1+ CIR-A2 transfected with PTH-rP gene, prostate carcinoma LNCaP cells, and autologous metastatic prostate cancer cells (M-CaP). These lymphocytes were not cytotoxic to HLA-A2.1+ targets not producing PTH-rP, such as peptide-unpulsed CIR-A2 and colon carcinoma SW-1463, cell lines. Our results provide evidence that PTR-4 peptide-pulsed autologous DC may break the tolerance of human TIL against the autologous tumour by inducing a PTH-rP-specific CTL immune reaction. In conclusion PTR-4 peptide-pulsed autologous DC may be a promising approach for vaccine-therapy and antigen-specific CTL adoptive immunotherapy of hormone-resistant prostrate cancer. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: prostate carcinoma, TIL, CTL epitope peptides, PTH-rP, human cancer immunotherapy

Full Text

The Full Text of this article is available as a PDF (125.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abrams S. I., Dobrzanski M. J., Wells D. T., Stanziale S. F., Zaremba S., Masuelli L., Kantor J. A., Schlom J., Masuelle L [corrected to Masuelli L. ]. Peptide-specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K-ras p21. Eur J Immunol. 1995 Sep;25(9):2588–2597. doi: 10.1002/eji.1830250928. [DOI] [PubMed] [Google Scholar]
  2. Arienti F., Belli F., Rivoltini L., Gambacorti-Passerini C., Furlan L., Mascheroni L., Prada A., Rizzi M., Marchesi E., Vaglini M. Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2. Cancer Immunol Immunother. 1993 May;36(5):315–322. doi: 10.1007/BF01741170. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bell D., Young J. W., Banchereau J. Dendritic cells. Adv Immunol. 1999;72:255–324. doi: 10.1016/s0065-2776(08)60023-1. [DOI] [PubMed] [Google Scholar]
  4. Böyum A. A one-stage procedure for isolation of granulocytes and lymphocytes from human blood. General sedimentation properties of white blood cells in a 1g gravity field. Scand J Clin Lab Invest Suppl. 1968;97:51–76. [PubMed] [Google Scholar]
  5. Cerundolo V., Alexander J., Anderson K., Lamb C., Cresswell P., McMichael A., Gotch F., Townsend A. Presentation of viral antigen controlled by a gene in the major histocompatibility complex. Nature. 1990 May 31;345(6274):449–452. doi: 10.1038/345449a0. [DOI] [PubMed] [Google Scholar]
  6. Coffey D. S. Prostate cancer. An overview of an increasing dilemma. Cancer. 1993 Feb 1;71(3 Suppl):880–886. doi: 10.1002/1097-0142(19930201)71:3+<880::aid-cncr2820711403>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  7. Correale P., Campoccia G., Tsang K. Y., Micheli L., Cusi M. G., Sabatino M., Bruni G., Sestini S., Petrioli R., Pozzessere D. Recruitment of dendritic cells and enhanced antigen-specific immune reactivity in cancer patients treated with hr-GM-CSF (Molgramostim) and hr-IL-2. results from a phase Ib clinical trial. Eur J Cancer. 2001 May;37(7):892–902. doi: 10.1016/s0959-8049(01)00063-6. [DOI] [PubMed] [Google Scholar]
  8. Correale P., Caraglia M., Fabbrocini A., Guarrasi R., Pepe S., Patella V., Marone G., Pinto A., Bianco A. R., Tagliaferri P. Bryostatin 1 enhances lymphokine activated killer sensitivity and modulates the beta 1 integrin profile of cultured human tumor cells. Anticancer Drugs. 1995 Apr;6(2):285–290. doi: 10.1097/00001813-199504000-00013. [DOI] [PubMed] [Google Scholar]
  9. Correale P., Procopio A., Celio L., Caraglia M., Genua G., Coppola V., Pepe S., Normanno N., Vecchio I., Palmieri G. Phorbol 12-myristate 13-acetate induces resistance of human melanoma cells to natural-killer- and lymphokine-activated-killer-mediated cytotoxicity. Cancer Immunol Immunother. 1992;34(4):272–278. doi: 10.1007/BF01741796. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Correale P., Tagliaferri P., Celio L., Genua G., Montagnani S., Bianco A. R. Verapamil upregulates sensitivity of human colon and breast cancer cells to LAK-cytotoxicity in vitro. Eur J Cancer. 1991;27(11):1393–1395. doi: 10.1016/0277-5379(91)90018-9. [DOI] [PubMed] [Google Scholar]
  11. Correale P., Walmsley K., Nieroda C., Zaremba S., Zhu M., Schlom J., Tsang K. Y. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst. 1997 Feb 19;89(4):293–300. doi: 10.1093/jnci/89.4.293. [DOI] [PubMed] [Google Scholar]
  12. Fenton R. G., Taub D. D., Kwak L. W., Smith M. R., Longo D. L. Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes. J Natl Cancer Inst. 1993 Aug 18;85(16):1294–1302. doi: 10.1093/jnci/85.16.1294. [DOI] [PubMed] [Google Scholar]
  13. Francini G., Petrioli R., Manganelli A., Cintorino M., Marsili S., Aquino A., Mondillo S. Weekly chemotherapy in advanced prostatic cancer. Br J Cancer. 1993 Jun;67(6):1430–1436. doi: 10.1038/bjc.1993.265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Frost P., Ng C. P., Belldegrun A., Bonavida B. Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity. Cell Immunol. 1997 Aug 25;180(1):70–83. doi: 10.1006/cimm.1997.1169. [DOI] [PubMed] [Google Scholar]
  15. Grabbe S., Beissert S., Schwarz T., Granstein R. D. Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? Immunol Today. 1995 Mar;16(3):117–121. doi: 10.1016/0167-5699(95)80125-1. [DOI] [PubMed] [Google Scholar]
  16. Guadagni F., Witt P. L., Robbins P. F., Schlom J., Greiner J. W. Regulation of carcinoembryonic antigen expression in different human colorectal tumor cells by interferon-gamma. Cancer Res. 1990 Oct 1;50(19):6248–6255. [PubMed] [Google Scholar]
  17. Guise T. A. Parathyroid hormone-related protein and bone metastases. Cancer. 1997 Oct 15;80(8 Suppl):1572–1580. doi: 10.1002/(sici)1097-0142(19971015)80:8+<1572::aid-cncr7>3.3.co;2-d. [DOI] [PubMed] [Google Scholar]
  18. Hortobagyi G. N. Bone metastases in breast cancer patients. Semin Oncol. 1991 Aug;18(4 Suppl 5):11–15. [PubMed] [Google Scholar]
  19. Houbiers J. G., Nijman H. W., van der Burg S. H., Drijfhout J. W., Kenemans P., van de Velde C. J., Brand A., Momburg F., Kast W. M., Melief C. J. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol. 1993 Sep;23(9):2072–2077. doi: 10.1002/eji.1830230905. [DOI] [PubMed] [Google Scholar]
  20. Jung S., Schluesener H. J. Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins. J Exp Med. 1991 Jan 1;173(1):273–276. doi: 10.1084/jem.173.1.273. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Luykx-de Bakker S. A., de Gruijl T. D., Scheper R. J., Wagstaff J., Pinedo H. M. Dendritic cells: a novel therapeutic modality. Ann Oncol. 1999 Jan;10(1):21–27. doi: 10.1023/a:1008349920664. [DOI] [PubMed] [Google Scholar]
  22. Markowicz S., Engleman E. G. Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro. J Clin Invest. 1990 Mar;85(3):955–961. doi: 10.1172/JCI114525. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Melero I., Bach N., Chen L. Costimulation, tolerance and ignorance of cytolytic T lymphocytes in immune responses to tumor antigens. Life Sci. 1997;60(23):2035–2041. doi: 10.1016/s0024-3205(96)00686-8. [DOI] [PubMed] [Google Scholar]
  24. Pierce W. C., Belldegrun A., Figlin R. A. Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal-cell carcinoma. Semin Oncol. 1995 Feb;22(1):74–80. [PubMed] [Google Scholar]
  25. Romani N., Reider D., Heuer M., Ebner S., Kämpgen E., Eibl B., Niederwieser D., Schuler G. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods. 1996 Sep 27;196(2):137–151. doi: 10.1016/0022-1759(96)00078-6. [DOI] [PubMed] [Google Scholar]
  26. Rosenberg S. A., Yang J. C., Schwartzentruber D. J., Hwu P., Marincola F. M., Topalian S. L., Restifo N. P., Sznol M., Schwarz S. L., Spiess P. J. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J Immunol. 1999 Aug 1;163(3):1690–1695. [PMC free article] [PubMed] [Google Scholar]
  27. Rosenberg S. A., Yannelli J. R., Yang J. C., Topalian S. L., Schwartzentruber D. J., Weber J. S., Parkinson D. R., Seipp C. A., Einhorn J. H., White D. E. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 1994 Aug 3;86(15):1159–1166. doi: 10.1093/jnci/86.15.1159. [DOI] [PubMed] [Google Scholar]
  28. Rubens R. D. Bone metastases--the clinical problem. Eur J Cancer. 1998 Feb;34(2):210–213. doi: 10.1016/s0959-8049(97)10128-9. [DOI] [PubMed] [Google Scholar]
  29. Tagliaferri P., Guarrasi R., Caraglia M., Morelli D., Fabbrocini A., Correale P., Bianco A. R. Tumour cell resistance to non-MHC-restricted lymphocytes: molecular mechanisms and clinical implications. Cancer Immunol Immunother. 1998 May;46(3):121–127. doi: 10.1007/s002620050470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Tjoa B. A., Simmons S. J., Bowes V. A., Ragde H., Rogers M., Elgamal A., Kenny G. M., Cobb O. E., Ireton R. C., Troychak M. J. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate. 1998 Jun 15;36(1):39–44. doi: 10.1002/(sici)1097-0045(19980615)36:1<39::aid-pros6>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  31. Topalian S. L., Muul L. M., Solomon D., Rosenberg S. A. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods. 1987 Aug 24;102(1):127–141. doi: 10.1016/s0022-1759(87)80018-2. [DOI] [PubMed] [Google Scholar]
  32. Topalian S. L., Solomon D., Rosenberg S. A. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol. 1989 May 15;142(10):3714–3725. [PubMed] [Google Scholar]
  33. Tsang K. Y., Zaremba S., Nieroda C. A., Zhu M. Z., Hamilton J. M., Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst. 1995 Jul 5;87(13):982–990. doi: 10.1093/jnci/87.13.982. [DOI] [PubMed] [Google Scholar]
  34. Vinholes J., Coleman R., Eastell R. Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment. Cancer Treat Rev. 1996 Jul;22(4):289–331. doi: 10.1016/s0305-7372(96)90021-3. [DOI] [PubMed] [Google Scholar]
  35. Vose B. M., Moore M. Human tumor-infiltrating lymphocytes: a marker of host response. Semin Hematol. 1985 Jan;22(1):27–40. [PubMed] [Google Scholar]
  36. Whiteside T. L., Parmiani G. Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use. Cancer Immunol Immunother. 1994 Jul;39(1):15–21. doi: 10.1007/BF01517175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Whiteside T. L. Tumor-infiltrating lymphocytes as antitumor effector cells. Biotherapy. 1992;5(1):47–61. doi: 10.1007/BF02194785. [DOI] [PubMed] [Google Scholar]
  38. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., Knuth A., Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991 Dec 13;254(5038):1643–1647. doi: 10.1126/science.1840703. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES